Last Updated 07:30:00 SGT
Based on a comprehensive analysis of the provided data, the future of IX Biopharma (42C.SG) $IX Biopharma(42C.SG) presents a high-risk, binary outcome. The company’s path is defined by a promising lon...
iX Biopharma has announced a non-binding term sheet with Orion Specialty Labs to form a joint venture in the U.S. iX will own 75 percent of the venture while Orion takes 25 percent and covers the capi...